|
Sponsored Research and License Agreements (Details) (USD $)
|
1 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 1 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
Other Agreements
|
Sep. 30, 2013
Other Agreements
Development event
|
Sep. 30, 2013
Other Agreements
Regulatory event
|
Sep. 30, 2013
Other Agreements
Product launch event
|
Jul. 31, 2012
Collaborations
AstraZeneca
|
Jun. 30, 2012
Collaborations
AstraZeneca
|
Apr. 30, 2010
Collaborations
AstraZeneca
Single unit of accounting
|
Sep. 30, 2010
Collaborations
AstraZeneca
Milestone achieved
|
Jul. 31, 2012
Collaborations
BerGenBio
|
Jun. 30, 2012
Collaborations
BerGenBio
|
Aug. 31, 2002
Collaborations
Daiichi
|
Sep. 30, 2013
Collaborations
Daiichi
|
Apr. 30, 2013
Collaborations
Daiichi
Milestone achieved
|
Jan. 31, 2012
Collaborations
Daiichi
Milestone achieved
|
|
| Collaborations | ||||||||||||||
| Upfront fee received | $ 1,000,000 | $ 100,000,000 | ||||||||||||
| Revenue recognized | 1,000,000 | 25,000,000 | 500,000 | |||||||||||
| Maximum amount of contingent payments receivable | 160,000,000 | 68,900,000 | 53,600,000 | 37,500,000 | ||||||||||
| Collaborative payment received | 500,000 | 1,400,000 | 750,000 | |||||||||||
| Cumulative amount of payments earned under collaborative arrangement | $ 7,900,000 | |||||||||||||
| Period of collaboration in research phase | 3 years | |||||||||||||